- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.03. | Taiho buys Swiss biotech and its ADC tech for $400M | ||
| 17.03. | Orca Bio to seek approval of T cell transplant after positive trial data | ||
| 17.03. | AstraZeneca adds 'in vivo' cell therapy capabilities with EsoBiotech deal | ||
| 17.03. | Latigo raises $150M to get non-opioid pain drugs through key tests | ||
| 17.03. | How biotech and pharma teams are reaching LPI ahead of schedule | ||
| 17.03. | NGS is changing GxP compliance. Will you adapt? | ||
| 14.03. | FDA sets flu shot recommendations without input of outside advisers | ||
| 14.03. | Makary advances to full senate vote; Acelyrin, Pliant adopt 'poison pills' | ||
| 13.03. | MeiraGTx spins Parkinson's, obesity gene therapies into AI startup | ||
| 13.03. | Mallinckrodt, Endo to combine in $7B deal | ||
| 12.03. | Roche broadens obesity drug plans with $1.65B Zealand Pharma deal | ||
| 12.03. | A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV | ||
| 12.03. | Flagship startup raises $200M in pursuit of 'scientific superintelligence' | ||
| 12.03. | Ono pays $280M to license Ionis rare disease drug | ||
| 11.03. | Douglas Kelly, deputy science director at FDA's device center, leaves agency | ||
| 11.03. | Viking inks CordenPharma deal to boost obesity drug supply | ||
| 11.03. | Merck opens $1B vaccine plant in North Carolina | ||
| 11.03. | Arvinas gets positive breast cancer data, but finds differentiation a hard sell | ||
| 11.03. | 2seventy bio, Bluebird's cell therapy spinout, sells to Bristol Myers for less than $300M | ||
| 10.03. | Beam base editing therapy gets 'proof of concept' in rare lung disease | ||
| 10.03. | Novo's Wegovy successor disappoints in second large trial | ||
| 10.03. | Mineralys shares climb on study data for blood pressure drug | ||
| 10.03. | SynWeave: Revolutionizing biopharma manufacturing by improving titer, timelines and manufacturability | ||
| 10.03. | 3 ways to accelerate development and de-risk cell and gene therapy manufacturing | ||
| 07.03. | J&J scraps depression testing for potential blockbuster drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
